Skip to nav Skip to content
Ronica  Nanda

Ronica Nanda, MD

Specialty: Radiation Oncology

Program: Radiation Oncology

Language(s): English

  • Overview

    Dr. Ronica Nanda is an Assistant Member in the Department of Radiation Oncology at Moffitt Cancer Center. Dr. Nanda will be located at Morton Plant Mease Hospital where she will support the partnership between Moffitt and BayCare. Dr. Nanda received her MD from the University of Florida. She completed a Radiation Oncology Residency at Emory University, where she also served as Chief Resident. She recently completed a Fellowship in Pediatric Proton Therapy at the University of Florida Health Proton Therapy Institute in Jacksonville. Dr. Nanda’s clinical interest is the treatment of breast cancers, lung cancers, brain tumors, and sarcomas. She also has a background in pediatric radiation oncology as well as in the use of proton therapy for adult and pediatric malignancies. Dr. Nanda’s primary research interests are on late effects of radiation therapy and cancer treatment. She has published numerous peer-reviewed manuscripts in high impact journals and has presented her research at multiple internationally-attended conferences. She is also passionate about studying survivorship issues for people with cancer. We are very excited to have Ronica join us and strengthen Moffitt’s ongoing relationship with the Baycare Health System.

    Education & Training

    Fellowship:

    • University of Florida Health Proton Therapy Institute - Pediatric Proton Therapy

    Residency:

    • Emory University School of Medicine - Internal Medicine/Radiation Oncology

    Medical School:

    • University of Florida College of Medicine - MD
  • Publications

    • Keit E, Nanda R, Johnstone PAS. Thirty-day mortality as a metric for palliative radiotherapy in pediatric patients. Curr Opin Support Palliat Care. 2024 Mar.18(1):65-69. Pubmedid: 38170195.
    • Nanda RH, Hua CH, Flampouri S, Eaton B, Kaste S, Patni T, Ronckers C, Constine LS, Marks LB, Esiashvili N. Risks of Spinal Abnormalities and Growth Impairment After Radiation to the Spine in Childhood Cancer Survivors: A PENTEC Comprehensive Review. Int J Radiat Oncol Biol Phys. 2023 Dec. Pubmedid: 38069918.
    • Gajjar A, Mahajan A, Abdelbaki M, Anderson C, Antony R, Bale T, Bindra R, Bowers DC, Cohen K, Cole B, Dorris K, Ermoian R, Franson A, Helgager J, Landi D, Lin C, Metrock L, Nanda R, Palmer J, Partap S, Plant A, Pruthi S, Reynolds R, Ruggieri P, Stearns D, Storm P, Wang A, Warren K, Whipple N, Zaky W, McMillian NR, Pluchino LA. Pediatric Central Nervous System Cancers, Version 2.2023, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Ne. 2022 Dec.20(12):1339-1362. Pubmedid: 36509072.
    • Mills MN, Russo NW, Fahey M, Nanda RH, Raiker S, Jastrzebski J, Stout LL, Wilson JP, Altoos TA, Allen KG, Blumencranz PW, Diaz R. Increased Risk for Ipsilateral Breast Tumor Recurrence in Invasive Lobular Carcinoma after Accelerated Partial Breast Irradiation Brachytherapy. Oncologist. 2021 Nov.26(11):e1931-e1938. Pubmedid: 34516030. Pmcid: PMC8571753.
    • Mills M, Liveringhouse C, Lee F, Nanda RH, Ahmed KA, Washington IR, Thapa R, Fridley BL, Blumencranz P, Extermann M, Loftus L, Balducci L, Diaz R. The prevalence of luminal B subtype is higher in older postmenopausal women with ER+/HER2- breast cancer and is associated with inferior outcomes. Geriatr Oncol. 2021 Mar.12(2):219-226. Pubmedid: 32859560. Pmcid: PMC7907245.
    • Dohm A, Diaz R, Nanda RH. The Role of Radiation Therapy in the Older Patient. Curr Oncol Rep. 2021 Jan.23(1):11. Pubmedid: 33387104.
    • Jim HSL, Hoogland AI, Brownstein NC, Barata A, Dicker AP, Knoop H, Gonzalez BD, Perkins R, Rollison D, Gilbert SM, Nanda R, Berglund A, Mitchell R, Johnstone PAS. Innovations in research and clinical care using patient-generated health data. CA-Cancer J Clin. 2020 May.70(3):182-199. Pubmedid: 32311776. Pmcid: PMC7488179.
    • Brown P, Inaba H, Annesley C, Beck J, Colace S, Dallas M, DeSantes K, Kelly K, Kitko C, Lacayo N, Larrier N, Maese L, Mahadeo K, Nanda R, Nardi V, Rodriguez V, Rossoff J, Schuettpelz L, Silverman L, Sun J, Sun W, Teachey D, Wong V, Yanik G, Johnson-Chilla A, Ogba N. Pediatric Acute Lymphoblastic Leukemia, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Ne. 2020 Jan.18(1):81-112. Pubmedid: 31910389.
    • Mills MN, Russo NW, Nanda RH, Wilson JP, Altoos TA, Caldwell DL, Stout LL, Dube S, Blumencranz PW, Allen KG, Diaz R. Management of ductal carcinoma in situ with accelerated partial breast irradiation brachytherapy: Implications for guideline expansion. Brachytherapy. 2020 Dec.20(2):345-352. Pubmedid: 33317964.
    • Nanda R, Boulware D, Baz R, Portman D, Yu HM, Jim H, Johnstone PAS. Patient-reported outcomes regarding radiation therapy in patients with multiple myeloma. Acta Oncol. 2020 Aug.59(8):983-987. Pubmedid: 32496846. Pmcid: PMC7771243.
    • Indelicato DJ, Bradley JA, Rotondo RL, Nanda RH, Logie N, Sandler ES, Aldana PR, Ranalli NJ, Beier AD, Morris CG, Mendenhall NP. Outcomes following proton therapy for pediatric ependymoma. Acta Oncol. 2018 May.57(5):644-648. Pubmedid: 29239262.
    • Mokhtech M, Rotondo RL, Bradley JA, Sandler ES, Nanda R, Logie N, Aldana PR, Morris CG, Indelicato DJ. Early outcomes and patterns of failure following proton therapy for nonmetastatic intracranial nongerminomatous germ cell tumors. Pediatr Blood Cancer. 2018 Jun.65(6):e26997. Pubmedid: 29380526.
    • Morgan TM, Danish H, Nanda RH, Esiashvili N, Meacham LR. Whole lung irradiation in stage IV Wilms tumor patients: Thyroid dosimetry and outcomes. Pediatr Blood Cancer. 2018 Feb.65(2). Pubmedid: 28960781.
    • Cassidy RJ, Zhang X, Switchenko JM, Patel PR, Shelton JW, Tian S, Nanda RH, Steuer CE, Pillai RN, Owonikoko TK, Ramalingam SS, Fernandez FG, Force SD, Gillespie TW, Curran WJ, Higgins KA. Health care disparities among octogenarians and nonagenarians with stage III lung cancer. Cancer. 2018 Feb.124(4):775-784. Pubmedid: 29315497. Pmcid: PMC5801133.
    • Nanda R, Flampouri S, Mendenhall NP, Indelicato DJ, Jones LM, Seeram VK, Hoppe BS. Pulmonary Toxicity Following Proton Therapy for Thoracic Lymphoma. Int J Radiat Oncol Biol Phys. 2017 Oct.99(2):494-497. Pubmedid: 28872001.
    • Nanda RH, Ganju RG, Schreibmann E, Chen Z, Zhang C, Jegadeesh N, Cassidy R, Deng C, Eaton BR, Esiashvili N. Correlation of Acute and Late Brainstem Toxicities With Dose-Volume Data for Pediatric Patients With Posterior Fossa Malignancies. Int J Radiat Oncol Biol Phys. 2017 Jun.98(2):360-366. Pubmedid: 28463155.
    • Nanda RH, Shehata BM, Khoshnam N, Durham M, Kim S, Selwanes W, Chen Z, Zhang C, Esiashvili N. Impact of lymph node evaluation in adjuvant and neoadjuvant chemotherapy settings on survival outcomes in Wilms tumour: a review of 185 cases from a single institution. Pathology. 2017 Jan.49(1):19-23. Pubmedid: 27913041.
    • Sayan M, Cassidy RJ, Butker EE, Nanda RH, Krishnamurti L, Khan MK, Esiashvili N. Gonadal shielding technique to preserve fertility in male pediatric patients treated with total body irradiation for stem cell transplantation. Bone Marrow Transplant. 2016 Jul.51(7):997-998. Pubmedid: 26950374.
    • Abugideiri M, Nanda RH, Butker C, Zhang C, Kim S, Chiang KY, Butker E, Khan MK, Haight AE, Chen Z, Esiashvili N. Factors Influencing Pulmonary Toxicity in Children Undergoing Allogeneic Hematopoietic Stem Cell Transplantation in the Setting of Total Body Irradiation-Based Myeloablative Conditioning. Int J Radiat Oncol Biol Phys. 2016 Feb.94(2):349-359. Pubmedid: 26853343.
    • Ganju RG, Nanda RH, Esiashvili N, Switchenko JM, Wasilewski-Masker K, Marchak JG. The Effect of Transition Clinics on Knowledge of Diagnosis and Perception of Risk in Young Adult Survivors of Childhood Cancer. J Pediat Hematol Onc. 2016 Apr.38(3):197-201. Pubmedid: 26925717. Pmcid: PMC4937789.
    • Kirkland RS, Nanda RH, Alazraki A, Esiashvili N. Influence of Pulmonary Nodules on Chest Computed Tomography and Risk of Recurrence in Stage IV Wilms Tumor. Int J Radiat Oncol Biol Phys. 2015 Jun.92(2):332-338. Pubmedid: 25754630.
    • Nanda RH, El-Rayes B, Maithel SK, Landry J. Neoadjuvant modified FOLFIRINOX and chemoradiation therapy for locally advanced pancreatic cancer improves resectability. J Surg Oncol. 2015 Jun.111(8):1028-1034. Pubmedid: 26073887.
    • Nanda RH, Liu Y, Gillespie TW, Mikell JL, Ramalingam SS, Fernandez FG, Curran WJ, Lipscomb J, Higgins KA. Stereotactic body radiation therapy versus no treatment for early stage non-small cell lung cancer in medically inoperable elderly patients: A National Cancer Data Base analysis. Cancer. 2015 Dec.121(23):4222-4230. Pubmedid: 26348268.
    • Kandula S, Prabhu RS, Nanda R, Switchenko JM, Cash T, Qayed M, Katzenstein H, Esiashvili N. Outcomes After Radiation Therapy to Metastatic Sites in Patients With Stage 4 Neuroblastoma. J Pediat Hematol Onc. 2015 Apr.37(3):175-180. Pubmedid: 25238225. Pmcid: PMC4869887.
    • Nanda R, Dhabbaan A, Janss A, Shu HK, Esiashvili N. The feasibility of frameless stereotactic radiosurgery in the management of pediatric central nervous system tumors. J Neurooncol. 2014 Apr.117(2):329-335. Pubmedid: 24549752.
    • Hazariwala R, Morris CG, Gilbert S, Algood C, Zlotecki RA. Radiotherapy for spermatic cord sarcoma. Am J Clin Oncol. 2013 Aug.36(4):392-394. Pubmedid: 22772428.
  • Patient Comments

    Overall Satisfaction

    0

    0 patients rated this provider

    The Provider Rating is an average of all responses to specific care provider-related questions from our nationally-recognized Press Ganey Patient Satisfaction Survey. Responses are measured on a scale of 1 to 5 with 5 being the best score.

    Patients that are treated in outpatient or hospital environments may receive different surveys, and the volume of responses will vary by question.

    Learn more about our patient satisfaction survey

     

    Comments

    Comments are gathered from specific care provider-related questions from our Patient Satisfaction Survey . The comments are submitted by patients and reflect their views and opinions. Patients are de-identified for confidentiality and patient privacy.

    We post both positive and negative comments from the surveys. We do not post comments that are libelous, slanderous, profane, irrelevant or otherwise inappropriate or may risk the privacy of our patients. A “[…]” in the comments below indicates de-identified patient information or comments that are unrelated to the patient’s experience with the visit to the provider, such as comments related to another provider, about the survey itself, or otherwise completely off-topic.

    Not all providers will have a star rating or comments. In order to ensure accuracy of our ratings, we only display ratings for providers who have a minimum of 30 completed from the previous 12 months.

    Learn more about our patient comments

    Provider Ratings and comments are gathered from our nationally-recognized Press Ganey Patient Satisfaction Survey. If a provider does not have ratings or comments listed it can be for several reasons, including:

    • The provider has not yet received the minimum number of patient satisfaction surveys to be eligible for display. We require a minimum of 30 surveys before we post results to ensure that the rating is statistically reliable and a true reflection of patient satisfaction.
    • He or she may be a researcher or other type of provider that does not see patients.
    • The provider practices in a specialty or office that does not use the specified surveys currently used for these ratings.

    Learn more about our patient satisfaction survey, ratings and comments

Find a Doctor